AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells

Summary: Cancer stem cells (CSCs) represent a small population of cancer cells that have the ability to self-renew and initiate tumors in vivo. CSCs are resistant to conventional therapies and are responsible for tumor relapse after chemotherapy and the development of distant metastases. Researchers at Purdue University have developed new techniques that have the potential for discovery and treatment of ovarian cancer stem cells. Using spectrometry imaging, researchers found significantly higher levels of unsaturated lipids in ovarian cancer stem cells as compared to differentiated cancer cells, which look more like normal cells. Lipid desaturases are enriched in CSCs, making them a stable, universal, and functional metabolic marker for CSCs and the target for CSC-specific therapy. This is a promising treatment for ovarian cancer as well as other types of cancer.

Technology Benefits: Strong marker potential Possible therapeutic target

Technology Application: Ovarian cancer diagnostics Ovarian cancer treatment Possible use for other cancers

Detailed Technology Description: Ji-Xin ChengCheng LaboratoryPurdue Biomedical EngineeringPurdue Chemistry

Countries: United States

Application No.: None

*Abstract

*Background: The American Cancer Society's 2017 ovarian cancer estimates are 22,440 new cases and 14,080 deaths in the United States. A major reason for the relatively large number of deaths is due to the fact that ovarian cancer is typically discovered in the later stages, making successful treatment more difficult. Currently, there is no reliable early detection test for ovarian cancer for all women. The standard treatment for ovarian cancer is surgery followed by radiation.

*IP Issue Date: None

*IP Type: Provisional

*Stage of Development: Prototype developed

*Web Links: Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipJi-Xin ChengCheng LaboratoryPurdue Biomedical EngineeringPurdue Chemistry

Country/Region: USA

For more information, please click Here